Format

Send to

Choose Destination
Oncol Lett. 2015 Nov;10(5):3274-3278. Epub 2015 Aug 27.

DNA copy number gains in malignant pleural mesothelioma.

Author information

1
Department of Thoracic, Breast and Endocrinological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Okayama 700-8558, Japan.
2
Department of Thoracic, Breast and Endocrinological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Okayama 700-8558, Japan ; Department of Clinical Genomic Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Okayama 700-8558, Japan.
3
Department of Thoracic, Breast and Endocrinological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Okayama 700-8558, Japan ; Department of Thoracic Surgery, National Hospital Organization Yamaguchi-Ube Medical Center, Ube, Yamaguchi 755-0241, Japan.
4
Department of Internal Medicine, Okayama Rosai Hospital, Okayama, Okayama 702-8055, Japan.
5
Department of Medical Oncology, National Hospital Organization Yamaguchi-Ube Medical Center, Ube, Yamaguchi 755-0241, Japan.
6
Department of Thoracic Surgery, National Hospital Organization Yamaguchi-Ube Medical Center, Ube, Yamaguchi 755-0241, Japan.
7
Division of Thoracic Surgery, Department of Cardiothoracic Surgery, New York University Langone Medical Center, NY 10016, USA.

Abstract

Malignant pleural mesothelioma (MPM) is a highly aggressive tumor with an extremely poor prognosis. The incidence of MPM is increasing as a result of widespread exposure to asbestos. The molecular pathogenesis of MPM remains unclear. The present study analyzed the frequency of various genomic copy number gains (CNGs) in MPM using reverse transcription-quantitative polymerase chain reaction. A total of 83 primary MPMs and 53 primary lung adenocarcinomas were analyzed to compare the CNGs of EGFR, KRAS, MET, FGFR1 and SOX2. In MPM, the CNGs of EGFR, KRAS, MET, FGFR1 and SOX2 were detected in 12 (14.5%), 8 (9.6%), 5 (6.0%), 4 (4.8%) and 1 (1.2%) of the samples, respectively. In lung adenocarcinomas, the CNGs of EGFR, KRAS, MET, FGFR1 and SOX2 were detected in 21 (39.6%), 12 (22.6%), 5 (9.4%), 10 (18.9%) and 0 (0.0%) of the samples, respectively. The CNGs of EGFR, KRAS and FGFR1 were significantly less frequent in the MPMs compared with the lung adenocarcinomas (P=0.0018, 0.048 and 0.018, respectively). Overall, the MPMs exhibited these CNGs less frequently compared with the lung adenocarcinomas (P=0.0002). The differences in CNGs between the two tumor types suggested that they are genetically different.

KEYWORDS:

copy number; lung adenocarcinoma; malignant pleural mesothelioma; reverse transcription-quantitative polymerase chain reaction

Supplemental Content

Full text links

Icon for PubMed Central
Loading ...
Support Center